Skip to content

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 10.20 EET Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

Orion Corporation has on 28 November 2019 received from Maa- ja vesitekniikan tuki ry a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which the total share of voting rights of the Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5% in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 28 November 2019.

According to the notification, the total share of voting rights of Maa- ja vesitekniikan tuki ry and Tukinvest Oy is 5.01%.

Total positions of Maa- ja vesitekniikan tuki ry and Tukinvest Oy:

 % of voting rights (a) % of votes through financial instruments (b) Total of both in % (a+b) Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached5.01%5.01%832,276,561
Position of previous notification (if applicable)-  ---
 % of shares (a) % of shares through financial instruments (b) Total of both in % (a+b) Total number of shares of issuer
Resulting situation on the date on which threshold was crossed or reached1.47%1.47%141,257,828
Position of previous notification (if applicable)-  ---

Notified details of the resulting situation on the date on which the threshold was crossed or reached::

Class/type of shares ISIN codeNumber of voting rights% of voting rights
 Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)
A share, FI000901436920,697,20020,970,0002.49%2.52%
B share, FI0009014377----
TOTAL41,667,2005.01%
Class/type of shares ISIN codeNumber of shares% of shares
 Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)
A share, FI00090143691,034,8601,048,5000.73%0.74%
B share, FI0009014377----
TOTAL2,083,3601.47%

Information in relation to person subject to the notification obligation:

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name% of voting rights% of voting rights through financial instrumentsTotal of both
Maa- ja vesitekniikan tuki ry2.49%-2.49%
Tukinvest Oy2.52%-2.52%
Name% of shares % of shares through financial instrumentsTotal of both
Maa- ja vesitekniikan tuki ry0.73%-0.73%
Tukinvest Oy0.74%-0.74%


Orion Corporation

Jari Karlson
CFO
 Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                    
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.